These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9512706)

  • 1. Influence of an antiviral compound on the temperature dependence of viral protein flexibility and packing: a molecular dynamics study.
    Phelps DK; Rossky PJ; Post CB
    J Mol Biol; 1998 Feb; 276(2):331-7. PubMed ID: 9512706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel basis of capsid stabilization by antiviral compounds.
    Phelps DK; Post CB
    J Mol Biol; 1995 Dec; 254(4):544-51. PubMed ID: 7500332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
    Speelman B; Brooks BR; Post CB
    Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
    Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
    J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of an antiviral compound from the internal pocket of human rhinovirus 14 capsid.
    Li Y; Zhou Z; Post CB
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7529-34. PubMed ID: 15899980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motion of an antiviral compound in a rhinovirus capsid under rotational symmetry boundary conditions.
    Yoneda S; Yoneda T; Kurihara Y; Umeyama H
    J Mol Graph Model; 2002 Aug; 21(1):19-27. PubMed ID: 12413027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human rhinovirus 14 complexed with fragments of active antiviral compounds.
    Bibler-Muckelbauer JK; Kremer MJ; Rossmann MG; Diana GD; Dutko FJ; Pevear DC; McKinlay MA
    Virology; 1994 Jul; 202(1):360-9. PubMed ID: 8009848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
    Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
    J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-ligand interactions: identification and characterization of ligand binding by NMR spectroscopy.
    Benie AJ; Moser R; Bäuml E; Blaas D; Peters T
    J Am Chem Soc; 2003 Jan; 125(1):14-5. PubMed ID: 12515488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses.
    Badger J; Minor I; Oliveira MA; Smith TJ; Rossmann MG
    Proteins; 1989; 6(1):1-19. PubMed ID: 2558377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dynamics investigation of the effect of an antiviral compound on human rhinovirus.
    Phelps DK; Post CB
    Protein Sci; 1999 Nov; 8(11):2281-9. PubMed ID: 10595531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human rhinovirus 3 at 3.0 A resolution.
    Zhao R; Pevear DC; Kremer MJ; Giranda VL; Kofron JA; Kuhn RJ; Rossmann MG
    Structure; 1996 Oct; 4(10):1205-20. PubMed ID: 8939746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal mode calculations of icosahedral viruses with full dihedral flexibility by use of molecular symmetry.
    van Vlijmen HW; Karplus M
    J Mol Biol; 2005 Jul; 350(3):528-42. PubMed ID: 15922356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Labeling of capsid proteins and genomic RNA of human rhinovirus with two different fluorescent dyes for selective detection by capillary electrophoresis.
    Kremser L; Petsch M; Blaas D; Kenndler E
    Anal Chem; 2004 Dec; 76(24):7360-5. PubMed ID: 15595880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN.
    Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC
    J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14.
    Zhang A; Nanni RG; Li T; Arnold GF; Oren DA; Jacobo-Molina A; Williams RL; Kamer G; Rubenstein DA; Li Y
    J Mol Biol; 1993 Apr; 230(3):857-67. PubMed ID: 8386772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of human rhinovirus serotype 2 (HRV2).
    Verdaguer N; Blaas D; Fita I
    J Mol Biol; 2000 Jul; 300(5):1179-94. PubMed ID: 10903863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving towards high-resolution descriptions of the molecular interactions and structural rearrangements of the human hepatitis B core protein.
    Freund SM; Johnson CM; Jaulent AM; Ferguson N
    J Mol Biol; 2008 Dec; 384(5):1301-13. PubMed ID: 18952101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure of antiviral agents that inhibit uncoating when complexed with viral capsids.
    Rossmann MG
    Antiviral Res; 1989 Feb; 11(1):3-13. PubMed ID: 2540708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein.
    Steindl TM; Crump CE; Hayden FG; Langer T
    J Med Chem; 2005 Oct; 48(20):6250-60. PubMed ID: 16190752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.